CBIO Smart Money
Crescent Biopharma, Inc.
1W: +3.2%
1M: -8.8%
3M: -22.4%
YTD: +15.2%
1Y: -0.2%
3Y: -90.2%
5Y: -93.4%
$13.27
+0.51 (+4.00%)
After Hours: $14.75 (+1.48, +11.15%)
Weekly Expected Move ±9.0%
$11
$12
$13
$14
$15
Credit Risk of going bust: lower than 71% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Crescent Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.4M against a stock market value of $474.0M.
Distance to default 7.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $718K (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' 4.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Crescent Biopharma, Inc. would be worth roughly what it owes.
Total debt $1.4M against a stock market value of $474.0M.
Distance to default 7.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $718K (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' 4.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 202694
Institutions Holding
+24 vs prior
109.7%
Ownership
+13.57%
34
New
17
Increased
26
Reduced
12
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | McNeill Jonathan | officer: president and coo | S-Sale | 3,839 | $16.71 | $64K | Filing |
| 2026-09-18 | Brumm Joshua T | officer: chief executive officer | S-Sale | 7,837 | $16.71 | $131K | Filing |
| 2026-09-16 | McNeill Jonathan | officer: president and coo | S-Sale | 731 | $17.90 | $13K | Filing |
| 2026-09-16 | Brumm Joshua T | officer: chief executive officer | S-Sale | 1,610 | $17.90 | $29K | Filing |
| 2026-09-16 | Bispham Barbara Harlin | officer: see remarks | S-Sale | 620 | $17.90 | $11K | Filing |
| 2026-09-16 | Scalzo Richard William | officer: chief financial officer | S-Sale | 568 | $17.90 | $10K | Filing |
| 2026-09-16 | Im Ellie Eunkyung | officer: chief medical officer | S-Sale | 623 | $17.90 | $11K | Filing |
| 2026-09-16 | Pinkas Jan | officer: chief scientific officer | S-Sale | 658 | $17.90 | $12K | Filing |
| 2026-09-16 | Lynch Ryan | officer: see remarks | S-Sale | 240 | $17.90 | $4K | Filing |
| 2026-07-16 | Fairmount Funds Management LLC | director | P-Purchase | 853,450 | $14.50 | $12.4M | Filing |
| 2026-07-16 | Fairmount Healthcare Fund II L.P. | director | P-Purchase | 853,450 | $14.50 | $12.4M | Filing |
| 2026-07-16 | Kiselak Tomas | director | P-Purchase | 853,450 | $14.50 | $12.4M | Filing |
| 2026-07-16 | Harwin Peter Evan | director | P-Purchase | 853,450 | $14.50 | $12.4M | Filing |
| 2026-06-22 | McNeill Jonathan | officer: president and coo | S-Sale | 20,549 | $17.99 | $370K | Filing |
| 2026-06-22 | Brumm Joshua T | officer: chief executive officer | S-Sale | 42,305 | $17.99 | $761K | Filing |
| 2026-06-22 | Im Ellie Eunkyung | officer: chief medical officer | S-Sale | 1,219 | $17.99 | $22K | Filing |
| 2026-06-22 | Bispham Barbara Harlin | officer: see remarks | S-Sale | 1,218 | $17.99 | $22K | Filing |
| 2026-06-22 | Scalzo Richard William | officer: chief financial officer | S-Sale | 1,112 | $17.99 | $20K | Filing |
| 2026-06-22 | Pinkas Jan | officer: chief scientific officer | S-Sale | 1,288 | $17.99 | $23K | Filing |
| 2026-06-22 | Lynch Ryan | officer: see remarks | S-Sale | 465 | $17.99 | $8K | Filing |
| 2025-12-15 | Doughty Christopher Grant | officer: chief business officer | A-Grant/Award | 8,000 | $— | $0 | Filing |
| 2025-12-15 | Pinkas Jan | officer: chief scientific officer | A-Grant/Award | 5,000 | $— | $0 | Filing |
| 2025-12-15 | Pinkas Jan | officer: chief scientific officer | A-Grant/Award | 17,507 | $— | $0 | Filing |
| 2025-12-15 | Doughty Christopher Grant | officer: chief business officer | A-Grant/Award | 14,714 | $— | $0 | Filing |
| 2025-12-15 | Scalzo Richard William | officer: chief financial officer | A-Grant/Award | 5,000 | $— | $0 | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| FMR LLC | 4,133,514 | $74M | — | 2026-06-30 | Filing |
| BVF INC/IL | 2,748,763 | $49M | — | 2026-06-30 | Filing |
| Fairmount Funds Management LLC | 2,747,866 | $49M | — | 2026-06-30 | Filing |
| Venrock Adviser, LLC | 2,133,576 | $38M | — | 2026-06-30 | Filing |
| Logos Global Management LP | 1,900,000 | $34M | +1,417,500 | 2026-06-30 | Filing |
| FCPM III SERVICES B.V. | 1,677,852 | $30M | — | 2026-06-30 | Filing |
| Balyasny Asset Management L.P. | 1,662,917 | $30M | +152,884 | 2026-06-30 | Filing |
| Vestal Point Capital, LP | 1,630,000 | $29M | +130,000 | 2026-06-30 | Filing |
| Opaleye Management Inc. | 1,319,351 | $24M | +6,736 | 2026-06-30 | Filing |
| BlackRock, Inc. | 1,271,762 | $23M | +1,156,037 | 2026-06-30 | Filing |
| TANG CAPITAL MANAGEMENT LLC | 1,160,000 | $21M | — | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 767,755 | $14M | -33,640 | 2026-06-30 | Filing |
| MILLENNIUM MANAGEMENT LLC | 403,859 | $7M | +80,306 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 384,576 | $7M | +280,355 | 2026-06-30 | Filing |
| JENNISON ASSOCIATES LLC | 378,507 | $7M | +225,533 | 2026-06-30 | Filing |
| NEXTBio Capital Management LP | 372,856 | $7M | — | 2026-06-30 | Filing |
| RTW INVESTMENTS, LP | 372,856 | $7M | — | 2026-06-30 | Filing |
| Remedium Capital Partners, LLC | 361,250 | $7M | +361,250 | 2026-06-30 | Filing |
| STATE STREET CORP | 315,587 | $6M | +276,520 | 2026-06-30 | Filing |
| AMERIPRISE FINANCIAL INC | 302,568 | $5M | +302,568 | 2026-06-30 | Filing |